You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

120 search results for: symposium

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

Rhinology
Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission
View more
Most Children With Atopic Dermatitis Have Uncontrolled Disease
expert video

Most Children With Atopic Dermatitis Have Uncontrolled Disease

Dermatology
Examine evidence from PEDI-BURDEN for the risk of flares in children with moderate-to-severe atopic dermatitis – a short soundbite from EADV 2022.
View more
Emerging Understanding of Chronic Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU
expert video

Emerging Understanding of Chronic Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU

Dermatology
Review the roles of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.
View more
New Perspectives on Disease Modification in Atopic Dermatitis - Panel Discussion
expert video

New Perspectives on Disease Modification in Atopic Dermatitis - Panel Discussion

Dermatology
Panel discussion exploring what disease modification could involve in atopic dermatitis.
View more
New Perspectives on Disease Modification in Atopic Dermatitis
expert video

New Perspectives on Disease Modification in Atopic Dermatitis

Dermatology
An exploration into the concept and potential of disease modification through therapeutic interventions in AD.
View more
Exploring The Concept of Disease Modification in Atopic Dermatitis
expert video

Exploring The Concept of Disease Modification in Atopic Dermatitis

Dermatology
Exploring the concept ​of disease modification and related pathomechanisms ​in atopic dermatitis​.
View more
The Impact of Advanced Systemic Therapies on Disease Control and Potential Remission in Atopic Dermatitis
expert video

The Impact of Advanced Systemic Therapies on Disease Control and Potential Remission in Atopic Dermatitis

Dermatology
Exploring the concept ​of disease modification relating to therapeutic interventions with targeted systemic therapies in atopic dermatitis​.
View more
Can Early Intervention Shape the Course of Atopic Dermatitis?
expert video

Can Early Intervention Shape the Course of Atopic Dermatitis?

Dermatology
Exploring the concept ​of disease modification through early intervention with targeted systemic therapies in atopic dermatitis​.
View more
Mast Cells and the Neuroimmune Axis in CSU
expert video

Mast Cells and the Neuroimmune Axis in CSU

Dermatology
A review of the neuroimmune mechanisms and activation of mast cells that result in itch in CSU.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases
expert video

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Dermatology
A review of the neuroimmune axis and the mechanisms involved in perpetuating chronic itch in AD, PN, and CSU.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: MacauChange country/region